Meeting
2020 ASCO Virtual Scientific Program
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
Presenter
Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03170960
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5564)
DOI
10.1200/JCO.2020.38.15_suppl.5564
Abstract #
5564
Poster Bd #
145
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Neeraj Agarwal, MD, FASCO
Videos & Slides
2023 ASCO Annual Meeting
APP Insights: Onboarding, Scope of Practice, and Maximizing Practice
Speaker: Todd Alan Pickard, FASCO
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study.
Speaker: Bradley Alexander McGregor, MD
Videos & Slides
2022 ASCO Annual Meeting
Panel Question and Answer with Dr. Simone Fishburn, Dr. Richard Pazdur, Dr. Marc Theoret, and Dr. Paul Kluetz
Speaker: Panel Discussion